

1 **Cycling, all-cause and cardiovascular mortality among persons with**
2 **diabetes: European Prospective Investigation into Cancer and**
3 **Nutrition (EPIC) cohort**

4

5 Subtitle: Cycling, diabetes and all-cause mortality

6 Date of revision: Nov. 23rd 2020

7 Word count: 3,299

8 Mathias Ried-Larsen, PhD^{1,2*}, mathias.ried-larsen@regionh.dk

9 Martin Gillies Rasmussen, MSc^{2,*}, mgrasmussen@health.sdu.dk

10 Kim Blond, MSc³, kim.blond.01@regionh.dk

11 Thure F. Overvad PhD⁴, t.overvad@rn.dk

12 Kim Overvad, PhD^{4,5}, ko@ph.au.dk

13 Karen Steindorf, PhD⁶, k.steindorf@dkfz-heidelberg.de

14 Verena Katzke, PhD⁶, V.Katzke@Dkfz-Heidelberg.de

15 Julie L.M. Andersen, MSc⁷, juan@cancer.dk

16 Kristina E. N. Petersen, MSc⁷, kripet@cancer.dk

17 Dagfinn Aune, PhD⁸, d.aune@imperial.ac.uk

18 Kostas K. Tsilidis, PhD^{8,10}, k.tsilidis@imperial.ac.uk

19 Alicia K. Heath, PhD⁸, a.heath@imperial.ac.uk

20 Keren Papier, PhD⁹, keren.papier@ndph.ox.ac.uk

21 Salvatore Panico, PhD¹¹, spanico@unina.it

22 Giovanna Masala, PhD¹², g.masala@ispro.toscana.it

23 Valeria Pala, ScD¹³, Valeria.Pala@istitutotumori.mi.it

24 Elisabete Weiderpass, PhD¹⁴, WeiderpassE@iarc.fr

25 Heinz Freisling, PhD¹⁴, FreislingH@iarc.fr

26 Manuela M. Bergmann, PhD¹⁵, bergmann@dife.de

27 W.M.Monique Verschuren, PhD^{16,17}, monique.verschuren@rivm.nl

28 Raul Zamora-Ros, PhD¹⁸, rzamora@idibell.cat

29 Sandra M. Colorado-Yohar, PhD^{19,20,21}, sandram.colorado@carm.es

30 Annemieke M.W. Spijkerman, PhD²², annemieke.spijkerman@rivm.nl

31 Matthias B. Schulze, DrPH^{23,24,25}, mschulze@dife.de

32 Eva MA. Ardanaz, PhD^{20,26,27}, me.ardanaz.aicua@navarra.es

33 Lars Bo Andersen, Dr.Med²⁸, lars.bo.andersen@hvl.no

34 Nick Wareham, PhD²⁹, nick.wareham@mrc-epid.cam.ac.uk

35 Søren Brage, PhD²⁹, Soren.Brage@mrc-epid.cam.ac.uk

36 Anders Grøntved, PhD.², agroentved@health.sdu.dk

37 ¹ Centre for Physical Activity Research, Rigshospitalet, Denmark, ² University of Southern Denmark, Denmark, ³ Bispebjerg and Frederiksberg Hospital,
38 Denmark, ⁴ Aalborg University, Denmark, ⁵ Aarhus University, Denmark, ⁶ German Cancer Research Center (DKFZ) Germany, ⁷ Danish Cancer Society,
39 Denmark, ⁸ Imperial College London, United Kingdom, ⁹ University of Oxford, United Kingdom, ¹⁰ University of Ioannina School of Medicine, Greece,
40 ¹¹ Federico II University Naples, Italy, ¹² Prevention and Clinical Network – ISPRO, Italy, ¹³ Fondazione IRCCS Istituto Nazionale dei Tumori di Milano,
41 ¹⁴ International Agency for Research on Cancer, France, ¹⁵ German Institute of Human Nutrition, Potsdam-Rehbruecke, Germany, ¹⁶ National Institute
42 for Public Health and the Environment, Netherlands, ¹⁷ Utrecht University, Netherlands, ¹⁸ Bellvitge Biomedical Research Institute (IDIBELL), Spain, ¹⁹
43 IMIB-Arrixaca, Spain, ²⁰ CIBER Epidemiología y Salud Pública (CIBERESP), Spain, ²¹ University of Antioquia, Colombia, ²² National Institute for
44 Public Health and the Environment (RIVM), Netherlands, ²³ Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-
45 Rehbruecke, Germany, ²⁴ German Center for Diabetes Research (DZD), Neuherberg, Germany, ²⁵ Institute of Nutritional Science, University of Potsdam,
46 Nuthetal, Germany, ²⁶ Navarra Public Health Institute, Spain, ²⁷ Navarra Institute for Health Research, Spain, ²⁸ Western Norway University of Applied
47 Sciences, Norway, ²⁹ University of Cambridge, UK

48
49 *These authors contributed equally to the study

50 Corresponding author: Mathias Ried-Larsen, Mathias.ried-larsen@regionh.dk, +4535450699

51
52
53
54

55 **KEY POINTS**

56 **Question:** Is cycling associated with risk of all-cause and cardiovascular mortality among persons
57 with diabetes?

58 **Findings:** In this prospective cohort study of 7,513 persons with diabetes, cycling was associated
59 with a $\geq 24\%$ lower all-cause mortality relative to non-cyclists, independent of other physical activity
60 and putative confounders. Taking up cycling over a 5-yr period was associated with a $\geq 35\%$ lower
61 risk of all-cause mortality relative to consistent non-cyclists.

62 **Meaning:** Our findings suggest that cycling could be encouraged as an activity for persons with
63 diabetes to lower the risk of mortality.

64 **ABSTRACT**

65 **Importance:** Premature death from all-causes and cardiovascular causes is higher among persons
66 with diabetes.

67 **Objective:** To investigate the association between time spent cycling and all-cause and
68 cardiovascular mortality among persons with diabetes, and to evaluate the association between
69 change in time spent cycling and risk of all-cause and cardiovascular mortality.

70 **Design:** Prospective cohort study

71 **Setting:** Questionnaires were administered in eight western European countries in 1992-2000
72 (baseline examination) and at a 2nd examination five years after baseline.

73 **Participants:** Adults with diabetes at the baseline examination (N=7,459) from the European
74 Prospective Investigation into Cancer and Nutrition study. A total of 5,423 participants with diabetes
75 completed both examinations.

76 **Exposures:** The primary exposure was self-reported time spent cycling per week at the baseline
77 examination. The secondary exposure was change in cycling status from the baseline to 2nd
78 examination.

79 **Main outcomes and measures:** The primary and secondary outcomes were all-cause and
80 cardiovascular mortality, adjusted for other physical activity modalities, diabetes duration, socio-
81 demographic and lifestyle factors.

82 **Results:** During 110,944 person-years of follow-up, 1,673 deaths from all-causes were registered.
83 Compared to the reference group of people who reported no cycling at baseline, the multivariable-
84 adjusted hazard ratios and 95% confidence intervals (95% CIs) for all-cause mortality were; 0.78
85 (0.61,0.99), 0.76 (0.65,0.88), 0.68 (0.57,0.82), and 0.76 (0.63,0.91) for cycling 1-59 min/week, 60-
86 149 min/week, 150-299 min/week and 300+ min/week, respectively. In an analysis of change in time
87 spent cycling with 57,802 person-years of follow-up, a total of 975 deaths from all causes were

88 recorded. Compared to people who reported no cycling at both examinations, the multivariable-
89 adjusted hazard ratios (95% CIs) for all-cause mortality were 0.90 (0.71,1.14) in those who cycled
90 and then stopped, 0.65 (0.46,0.92) in initial non-cyclists who started cycling, and 0.65 (0.53,0.80) for
91 people who reported cycling at both examinations. Similar results were observed for cardiovascular
92 mortality.

93 **Conclusion and relevance:** Cycling was associated with lower all-cause and cardiovascular
94 mortality risk among people with diabetes independent of practicing other types of physical activity.
95 Participants who took up cycling between the baseline and second examination had a significantly
96 lower risk of both all-cause and cardiovascular mortality compared to consistent non-cyclists.

97

98

99 **BACKGROUND**

100 Premature death from all-causes and cardiovascular disease (CVD) is higher among people with
101 diabetes¹. Regular physical activity is a critical behavioral target in the management of diabetes², but
102 only structured exercise, in contrast to advice only, has been shown to improve CVD risk factors³⁻⁶.
103 Thus, it is necessary to investigate the influence of engagement in specific unstructured physical
104 activities on mortality in this patient population.

105 Cohort studies in populations with diabetes have reported inverse associations between
106 overall physical activity, leisure-time physical activity (LTPA), and walking with all-cause and CVD
107 mortality⁷. However, associations with walking have been inconsistent, likely because only moderate-
108 intensity walking appears to be associated with a reduced risk of all-cause and CVD mortality⁸.
109 Meeting the physical activity recommendations both in terms of total physical activity volume as well
110 as intensity is a major challenge, especially in people with diabetes⁹⁻¹¹. As lack of time is often quoted
111 as a barrier, incorporating activities into everyday life, may be an effective strategy. Cycling is a
112 potential candidate activity to replace motorized transport for short-to-medium distance trips, e.g.
113 during commuting to work without a substantial impact on time use. As moderate-to-high intensities
114 are reached during cycling at self-selected paces in adults¹²⁻¹⁵, cycling could decrease the risk of
115 premature mortality. It may also be a feasible strategy as cycling is one of the preferred activities in
116 people with type 2 diabetes^{16,17}. It is well-established that there is a strong association between cycling
117 and improvements in cardiovascular risk factors, reduced risk of all-cause, and cause-specific
118 mortality, such as CVD, in the general population¹⁸⁻²⁰. There are, however, to our knowledge, no
119 studies that have examined the role of cycling in preventing premature mortality in people with
120 diabetes.

121 The primary aim of the study was to investigate the relationship between cycling and
122 all-cause and CVD mortality among individuals with diabetes from European countries. A secondary

123 aim was to study the relationship between change in cycling over a 5-year period and all-cause and
124 CVD mortality.

125

126 **METHODS**

127 **Study design and setting**

128 The study is a prospective cohort study of people with diabetes at baseline in the European
129 Prospective Investigation into Cancer and Nutrition (EPIC) cohort²¹. In EPIC, 23 centers in 10
130 western European countries collected information on nutrition, lifestyle, anthropometry and medical
131 history from more than 521,234 males and females participating²¹. Medical history, socio-
132 demographic and lifestyle information was assessed by questionnaires at baseline between the year
133 1992-2000 (baseline examination) and at the second examination, on average 4.9 years (SD 2.1) after
134 the baseline collection. Data were only available from 22 centers as data from Greece was not released
135 for this study. The ethical review boards from the International Agency for Research on Cancer
136 (IARC) and all local participating centers approved this study. All participants signed an informed
137 consent.

138

139 **Study population**

140 From the entire EPIC population, people with diabetes at the baseline assessment, were included in
141 the present study. Diabetes was self-reported and/or verified by a second source (at least one),
142 including repeated self-report, by a general physician, linkage to register/medical record at a later
143 point, prescription of use of glucose lowering/diabetes related medication, baseline glycated
144 hemoglobin \geq 6.0% (42 mmol/mol)⁷.

145

146 **Data collection**

147 Study procedures have been described in detail elsewhere²¹. Briefly, height, weight, and waist
148 circumference were measured using similar protocols across study centers²¹. Body mass index was
149 calculated as weight in kilograms divided by height in metres squared (kg/m²). Central obesity was
150 defined according the International Diabetes Federation criteria²². Diabetes duration was calculated
151 as the time from self-reported age/calendar year of medical diagnosis to baseline.

152 Dietary intake, including alcohol consumption, was assessed by a questionnaire
153 (quantitative, semi-quantitative, or a combination), and 7- or 14-day-record, and individual energy
154 and nutrient intake was based on the standardized EPIC Nutrient Database (ENDB)^{21,23}. As the
155 Mediterranean diet is associated with improved metabolic control and decreased risk of diabetes²⁴⁻²⁶,
156 this was included as a covariate expressed as the relative Mediterranean diet score (rMED)^{24,26,27}.
157 Dietary data was only available for the baseline examination.

158

159 **Assessment of physical activity**

160 Information about physical activity habits was obtained from a lifestyle questionnaire and included
161 information about duration and frequency of cycling, walking, gardening, do-it-yourself activities,
162 household work, sports, number of stairs climbed, and occupational physical activity^{21,28}. Weekly
163 time spent cycling to/from work and leisure time during winter and summer was averaged into a
164 single variable of total annual cycling time and then categorized as: 0, 1-59, 60-149, 150-299 and
165 300+ minutes/week. Change in total cycling from baseline to the second examination was categorized
166 based on total time spent cycling at the two examinations 1) non-cycling - participants who reported
167 zero minutes of cycling at both examinations, 2) people who stopped cycling - those who reported
168 cycling (any amount) at the baseline but not the second examination, 3) people who started cycling -
169 participants who did not report cycling at baseline but did report cycling (any amount) at the second
170 examination or 4) those who were consistent cyclists at both examinations.

171 LTPA energy expenditure (without cycling included – from here on denoted LTPA)
172 (metabolic equivalent of task -MET-h/week) was calculated at both examinations as the sum of
173 energy expenditures from the following activities: gardening, do-it-yourself activities, stair-climbing,
174 housework activities, walking, and sports. The MET-h/week expresses the intensity of physical
175 activity (PA) as multiples of the resting metabolic rate¹⁴. As information on stair-climbing was only
176 available from four study centers at the second examination, this activity was not included in the
177 second examination LTPA variable. Occupational physical activity was reported in categories of
178 sedentary occupation, standing occupation, manual/heavy manual work, or non-worker²⁸.

179

180 **Outcome ascertainment**

181 The primary and secondary outcomes were all-cause and CVD mortality, respectively. CVD deaths
182 were coded according to the *International Classification of Diseases, Injuries, and Causes of Death,*
183 *Tenth Revision*, using the codes I00-I99. Vital status and cause of death were obtained through record
184 linkage with national, regional or local registries, regional health departments, physicians or hospitals,
185 active follow-up, or health insurance²⁹.

186

187 **Statistical analysis**

188 A statistical analysis plan was developed (see supplementary material), published at
189 <http://aktivsundhed.dk/da/cfas-forskning/publikationsliste>, and pre-registered at
190 www.clinicaltrials.gov (identifier NCT04171557) prior to commencing the analyses. The risks of all-
191 cause and CVD mortality were computed as hazard ratios (HRs) with 95% confidence intervals (CIs)
192 according to weekly time spent cycling at baseline estimated using stratified Cox proportional hazard
193 regression models with age as the underlying time scale. Analyses were corrected for delayed entry.
194 Participants were considered ‘at-risk’ from age at baseline examination in the primary analyses and

195 from age at the second examination in the analyses of change in cycling. Participants leaving the
196 study during follow-up due to emigration or premature withdrawal were right censored at the age of
197 emigration or withdrawal. As the associations between baseline cycling, all-cause or CVD mortality
198 were non-linear, we computed restricted cubic splines of the respective relationships with knot
199 placements at the 10th, 50th and 90th percentiles as recommended by Harrell³⁰. Due to large amounts
200 of zero values in the cycling variable, the percentiles were computed excluding zero.

201 A crude model (Model 1) was fitted with categories of cycling as exposure (0
202 (reference), 1-59, 60-149, 150-299 and 300+ minutes/week) and adjusted for sex and age (years) and
203 further stratified by study center to adjust for confounding of this variable. The proportional hazards
204 assumption for cycling was met within each stratum. Model 1 was further adjusted for attained
205 educational level (no formal education, primary school, technical school, secondary school, or
206 university degree), smoking status (never-smoker, former smoker, or current smoker), diabetes
207 duration (years), adherence to the Mediterranean diet score (categories of the rMED score, low: 0–6
208 points, medium: 7–10 points, or high: 11–18 points)^{24,26}, total energy intake (quartiles of kcal/day)²³,
209 physical activity excluding cycling (quartiles of LTPA energy expenditure), and occupational PA
210 (sedentary occupation, standing occupation, manual/heavy manual work, non-worker or unknown
211 status) (Model 2, main model). Finally, prevalent stroke, (yes/no), previous myocardial infarction
212 (MI, (yes/no)), prevalent cancer (yes/no), hypertension (yes/no), hyperlipidemia (yes/no), and central
213 obesity (yes/no) at baseline were added as covariates (Model 3). Effect modification by sex and
214 diabetes duration (≥ 5 vs. < 5 years) was evaluated statistically using the likelihood-ratio test by
215 comparing Model 2 adding a multiplicative interaction term for sex or diabetes duration and cycling
216 with a model including only main effects (Model 2). Because several covariates did not meet the
217 proportional hazard assumption in the multivariable Models 2 and 3, we computed an extended Cox
218 regression analysis where we stratified by study center and energy intake in the analyses with the all-

219 cause mortality as the outcome. In the Models with CVD mortality as the outcome, we stratified by
220 study center, educational level, and LTPA (excluding cycling). We conducted a range of pre-planned
221 sensitivity analyses for the primary model (*Model 2*) specified in *the statistical analysis plan* to
222 investigate the impact of residual confounding and reverse causality (excluding all deaths and CVD
223 deaths within the first 2 years following the baseline examination).

224 In the pre-planned secondary analysis, associations between all-cause and CVD
225 mortality, and change (from baseline to second examination) in cycling were investigated. The
226 associations were initially adjusted for sex and age at the second examination and stratified by study
227 center. A multivariable model was fitted additionally adjusting for educational level at baseline,
228 smoking status at both examinations, diabetes duration at the time of second examination, leisure-
229 time physical activity excluding cycling at both examinations, and occupational physical activity at
230 the second survey). The multivariable analyses were stratified by study center, baseline occupational
231 physical activity, adherence to the relative Mediterranean diet and total energy intake at baseline.

232 Ten-year adjusted (standardized) cumulative mortality according to cycling at baseline
233 or change in cycling status, consistent with the primary models, were estimated using flexible
234 parametric survival models³¹, with additional post estimation of adjusted differences (95% CI) in 10-
235 year cumulative mortality comparing 0 min/week of cycling at baseline and/or at the second
236 examination to higher levels of cycling or stopping/starting/maintaining cycling.

237 All analyses were conducted using STATA IC V.16.1 (STATA Corp, College Station,
238 Texas, USA) using $\alpha=0.05$ (2-sided).

239 **RESULTS**

240 Of the 492,763 participants enrolled into the EPIC cohort, 10,995 had diabetes at the baseline
241 examination. The analytic sample consisted of 7,459 participants (63% with confirmed diabetes) with
242 a mean age (standard deviation ((SD)) of 55.9 (7.7) years, a mean diabetes duration (SD) of 7.7 (8.1)
243 years and of who 52.6 % were female. Baseline characteristics are shown in Table 1 and the flow of
244 participants with main reasons of exclusion is found in eFigure 1.

245 The participants were followed for a mean (SD) of 14.9 (4.4) years (110,944 person-
246 years) with 1,673 deaths from all-causes and 811 deaths attributable to CVD. A subset of participants
247 also completed the 2nd examination and were included in the analysis of change in cycling (n=5,423).
248 This analysis had a mean (SD) of 10.7 (4.3) years follow-up accumulating a total of 57,802 person-
249 years with 975 deaths from all-causes and 429 from CVD.

250

251 **Baseline cycling, all-cause and CVD mortality**

252 Time spent cycling at baseline was inversely associated with the risk of all-cause and CVD mortality
253 in the crude model (Table 2, Model 1). A lower HR for all-cause mortality was observed for all people
254 reporting any cycling (>0 min/week), when compared to non-cyclists. Cycling was also associated
255 with a reduced risk of CVD mortality (Table 2). Adjusting for educational level, lifestyle risk factors,
256 and diabetes duration did not materially affect the relationship between cycling and all-cause
257 mortality (Table 2, Model 2). Adjusted 10-year cumulative mortality per category is found in eTable
258 1 and eFigure 2. The cumulative mortality risk difference (RD) relative to 0 min/week of cycling for
259 ascending cycling categories were of -1.9%, -2.0%, -2.7%, and -2.1% for all-cause mortality and -
260 1.2%, -1.2%, -2.2%, and -1.0% for CVD mortality, respectively (eTable 1). No significant
261 multiplicative interactions of sex or diabetes duration and cycling were observed for all-cause nor
262 CVD mortality. Further adjustment for existing conditions and CVD risk factors only slightly

263 attenuated the associations (Table 2, Model 3). Sensitivity analyses investigating residual
264 confounding by smoking, sports participation, self-reported diabetes and reverse causality broadly
265 confirmed the associations between cycling and both all-cause and CVD mortality (eTable 3).

266 The dose-response relationship with baseline cycling as a continuous variable for both
267 all-cause and CVD mortality was modelled (Figure 1). For comparison, the relationship for LTPA
268 (excluding cycling) is provided. This revealed a reversed J-shaped association between both outcomes
269 and cycling and a linear association for LTPA (excluding cycling) (HRs (95% CIs) per 10 MET-h
270 increase per week: 0.97 (0.95, 0.98) and 0.96 (0.94, 0.98) for all-cause and CVD mortality,
271 respectively) (Figure 1).

272

273 **Change in cycling and all-cause and CVD mortality**

274 The associations between change in cycling between baseline and second examination (no cycling,
275 ceased, initiated, and continued cycling) , and all-cause and CVD mortality are shown in Figure 2.
276 For both outcomes, HRs were $\geq 35\%$ lower among participants who started or maintained cycling
277 (Figure 2) relative to non-cyclist (RD relative to non-cyclist were -3.7% for all-cause and -2.7% for
278 CVD mortality, eTable 2, eFigure 3). After excluding deaths within the first two years from the
279 follow-up examination, the associations were unchanged; HRs (95% CIs) for all-cause mortality were
280 0.93 (0.72, 1.19), 0.66 (0.45, 0.95), and 0.64 (0.51, 0.80) for people who stopped, started or
281 maintained cycling, compared to non-cyclists. Corresponding HRs (95% CIs) for CVD mortality
282 were 1.08 (0.77, 1.51), 0.56 (0.31, 0.99), and 0.54 (0.39, 0.75).

283

284 **DISCUSSION**

285 In this European prospective cohort study, we observed that time spent cycling was associated with
286 a lower risk of all-cause and CVD mortality in people with diabetes, independent of other physical

287 activities, sociodemographic factors and a range of other lifestyle and clinical risk factors including
288 diet quality and central obesity. Change over time in cycling was also related to mortality risk, with
289 a significantly lower mortality risk for people with diabetes who took up cycling between two
290 examinations five years apart.

291 The importance of cycling in relation to mortality risk has been studied extensively in disease
292 free populations^{12,19,20,32}, and the associated relative risks for all-cause and CVD mortality associated
293 with cycling in this study in people with diabetes, were similar in magnitude and direction³³⁻³⁸. The
294 lower risk of all-cause and CVD mortality associated with overall physical activity as well as walking
295 among persons with diabetes is well established^{7,8,39-45}. This investigation extends the level of
296 evidence within this field by documenting that cycling and taking up cycling may offer specific health
297 benefits in people with diabetes over and above other physical activities, including walking. Mixed-
298 mode commuting (walking and/or cycling) has been associated with decreased mortality in person
299 with diabetes⁴⁶. However, the association was weaker as compared to our observations. As physical
300 activity intensity is important in mediating the health benefits from walking among people with type
301 2 diabetes^{8,47}, a lower intensity of physical activity, such as walking, when compared to cycling, may
302 account for differences¹⁴. The lower risk of all-cause and CVD mortality observed in consistent
303 cyclists or persons initiating cycling may be mediated by improvements in aerobic fitness which is
304 associated with all-cause and CVD mortality^{45,48}.

305 While it is biologically plausible that regular engagement in cycling would reduce all-cause
306 and CVD mortality in persons with diabetes, the dose-response curves are ambiguous. It is important
307 to note that only a few diabetic participants reported very high volumes of cycling, and the confidence
308 intervals are very wide, and we cannot not reject the existence of a monotonic dose-response
309 relationship. Also, the analysis of change in cycling habits over a five-year period showed lower
310 mortality risk among diabetic people who started cycling compared with those, which provide support

311 of a possible causal relationship. However, we cannot exclude other causes of the indication of a
312 reversed j-shaped relationship or lack of a monotonic relationship between cycling and mortality in
313 diabetic people. The “upstick” in risk at high volumes can also relate to an increased risk of fatal
314 injuries with increased cycling, e.g. in urban settings or increased risk of CVD or respiratory diseases
315 due exposure to air pollutants during cycling in settings with dense motorized traffic⁴⁹⁻⁵¹. In addition,
316 the beneficial effects of physical activity on cardiovascular risk factors with increasing air pollutants
317 may be attenuated⁵²⁻⁵⁵. However, previous cohort studies have reported that levels of traffic-related
318 air pollution did not modify the inverse association of outdoor physical activity with mortality or
319 incidence of heart disease.^{33,56,57} Although air pollution during exercise may decrease lung function
320 acutely^{52,54,55,58}, it seems that the benefits of physical activity on the risk of asthma and COPD is
321 maintained when performed in moderately polluted settings such as urban environments⁵⁹. As cycling
322 is associated with an increased risk of fatal injuries compared with⁴⁹, this may also explain the small
323 “upstick” in all-cause mortality risk with increased cycling, but cannot explain the corresponding
324 shape of the curve for CVD mortality. Of note, commuter cycling may increase the risk of injuries
325 and hospital admissions compared to non-active commuting in the general populations⁴⁹. However,
326 the health benefits of cycling may outweigh the increased risk of injuries due to a decreased risk of
327 morbidities in cyclists⁶⁰. Finally, bias due to uncontrolled confounding and reverse causation may
328 also explain the lack of a monotonic relationship.

329

330 **Strengths and limitations**

331 The study includes a range of countries including those with established cycling infrastructures and
332 cultures, such as Denmark and The Netherlands and others where cycling is less common. The
333 inclusion of data from a follow-up examination approximately 5 years after baseline examination

334 which allowed us to investigate within-person change in cycling exposure and its relationship with
335 subsequent mortality risk.

336 Limitations of the study include the inability to distinguish between type 1 and type 2
337 diabetes. Generally, type 2 diabetes accounts for 90% of all diabetes cases in adults⁶¹. Therefore, we
338 assume our findings primarily apply to persons with type 2 diabetes. To maximize the analytic
339 sample, we chose to include both self-reported cases and diabetes cases confirmed through other
340 sources, which increases the risk of misclassification. However, only few numerical differences were
341 observed in the characteristics between confirmed and self-reported diabetes (eTable 2). Also,
342 findings from a sensitivity analysis, where we restricted to those with confirmed diabetes cases only,
343 supported our overall findings. Although we adjusted the analyses for a range of potential
344 confounders, these were mostly self-reported and thus prone to misclassification. Although slightly
345 attenuated, the associations observed for all-cause and CVD mortality were confirmed in sensitivity
346 analyses, when ever-smokers and people reporting engaging in any sports, were excluded. This
347 suggests that residual confounding by smoking and sports-related physical activity may be minor,
348 although the 95% CIs for the latter were wide for CVD mortality. A concern may be confounding by
349 concomitant pharmacological intervention. However, as pharmacological intervention intensifies
350 with increasing diabetes duration⁶², and as we consistently adjust for diabetes duration, we may, to
351 some extent, have addressed this issue in our analyses. As the prevalence of micro- and macrovascular
352 complications are highly prevalent among persons with diabetes⁶³, persons with a history of CVD at
353 baseline were included in the primary analyses to increase the generalizability of the findings.
354 However, such complications may limit engagement in physical activity, including cycling, thus
355 increase the risk of reverse causation. Our sensitivity analyses excluding participants with a history
356 of MI, stroke, and prevalent cancer as well as all those dying within 2 years of follow-up did however
357 not materially change the interpretation. Finally, we decided *a priori*, only to include participants

358 with complete data for all statistical models, which could have introduced selection bias and limited
359 generalizability. However, rerunning the analyses with missing data statistically imputed for cycling
360 and confounders, confirmed our findings. The results may not be generalizable to people using
361 electric cycles.

362 In conclusion, engaging in cycling was related to a lower risk of all-cause and CVD
363 mortality among people with diabetes after considering other physical activities, as well as other risk
364 factors.

365

366

367 **REFERENCES**

368

- 369 1. Roglic G, Unwin N. Mortality attributable to diabetes: estimates for the year 2010. *Diabetes*
370 *research and clinical practice*. 2010;87(1):15-19.
- 371 2. Colberg SR, Sigal RJ, Yardley JE, et al. Physical Activity/Exercise and Diabetes: A Position
372 Statement of the American Diabetes Association. *Diabetes care*. 2016;39(11):2065-2079.
- 373 3. Umpierre D, Ribeiro PA, Kramer CK, et al. Physical activity advice only or structured
374 exercise training and association with HbA1c levels in type 2 diabetes: a systematic review
375 and meta-analysis. *JAMA : the journal of the American Medical Association*.
376 2011;305(17):1790-1799.
- 377 4. Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control
378 and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. *JAMA*
379 *: the journal of the American Medical Association*. 2001;286(10):1218-1227.
- 380 5. Chudyk A, Petrella RJ. Effects of exercise on cardiovascular risk factors in type 2 diabetes: a
381 meta-analysis. *Diabetes care*. 2011;34(5):1228-1237.
- 382 6. Hayashino Y, Jackson JL, Fukumori N, Nakamura F, Fukuhara S. Effects of supervised
383 exercise on lipid profiles and blood pressure control in people with type 2 diabetes mellitus:
384 a meta-analysis of randomized controlled trials. *Diabetes research and clinical practice*.
385 2012;98(3):349-360.
- 386 7. Sluik D, Buijsse B, Muckelbauer R, et al. Physical Activity and Mortality in Individuals With
387 Diabetes Mellitus: A Prospective Study and Meta-analysis. *Archives of internal medicine*.
388 2012;172(17):1285-1295.
- 389 8. Gregg EW, Gerzoff RB, Caspersen CJ, Williamson DF, Narayan KM. Relationship of
390 walking to mortality among US adults with diabetes. *Archives of internal medicine*.
391 2003;163(12):1440-1447.
- 392 9. Zhao G, Ford ES, Li C, Mokdad AH. Compliance with physical activity recommendations in
393 US adults with diabetes. *Diabetic medicine : a journal of the British Diabetic Association*.
394 2008;25(2):221-227.
- 395 10. Morrato EH, Hill JO, Wyatt HR, Ghushchyan V, Sullivan PW. Physical activity in U.S. adults
396 with diabetes and at risk for developing diabetes, 2003. *Diabetes care*. 2007;30(2):203-209.
- 397 11. van der Berg JD, Stehouwer CD, Bosma H, et al. Associations of total amount and patterns
398 of sedentary behaviour with type 2 diabetes and the metabolic syndrome: The Maastricht
399 Study. *Diabetologia*. 2016;59(4):709-718.
- 400 12. Blond MB, Rosenkilde M, Gram AS, et al. How does 6 months of active bike commuting or
401 leisure-time exercise affect insulin sensitivity, cardiorespiratory fitness and intra-abdominal
402 fat? A randomised controlled trial in individuals with overweight and obesity. *British journal*
403 *of sports medicine*. 2019.
- 404 13. Berntsen S, Malnes L, Langaker A, Bere E. Physical activity when riding an electric assisted
405 bicycle. *The international journal of behavioral nutrition and physical activity*.
406 2017;14(1):55.
- 407 14. Ainsworth BE, Haskell WL, Whitt MC, et al. Compendium of physical activities: an update
408 of activity codes and MET intensities. *Medicine and science in sports and exercise*. 2000;32(9
409 Suppl):S498-504.
- 410 15. Oja P, Mänttari A, Heinonen A, et al. Physiological effects of walking and bicycling to work.
411 *Scandinavian journal of medicine & science in sports*. 1991;1:151-157.

- 412 16. Forbes CC, Plotnikoff RC, Courneya KS, Boule NG. Physical activity preferences and type 2
413 diabetes: exploring demographic, cognitive, and behavioral differences. *The Diabetes*
414 *educator*. 2010;36(5):801-815.
- 415 17. Wanko NS, Brazier CW, Young-Rogers D, et al. Exercise preferences and barriers in urban
416 African Americans with type 2 diabetes. *The Diabetes educator*. 2004;30(3):502-513.
- 417 18. Kelly P, Kahlmeier S, Gotschi T, et al. Systematic review and meta-analysis of reduction in
418 all-cause mortality from walking and cycling and shape of dose response relationship. *The*
419 *international journal of behavioral nutrition and physical activity*. 2014;11:132.
- 420 19. Nordengen S, Andersen LB, Solbraa AK, Riiser A. Cycling and cardiovascular disease risk
421 factors including body composition, blood lipids and cardiorespiratory fitness analysed as
422 continuous variables: Part 2-systematic review with meta-analysis. *British journal of sports*
423 *medicine*. 2019.
- 424 20. Nordengen S, Andersen LB, Solbraa AK, Riiser A. Cycling is associated with a lower
425 incidence of cardiovascular diseases and death: Part 1 - systematic review of cohort studies
426 with meta-analysis. *British journal of sports medicine*. 2019.
- 427 21. Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and
428 Nutrition (EPIC): study populations and data collection. *Public health nutrition*.
429 2002;5(6B):1113-1124.
- 430 22. Alberti KG, Zimmet P, Shaw J, Group IDFETFC. The metabolic syndrome--a new worldwide
431 definition. *Lancet*. 2005;366(9491):1059-1062.
- 432 23. Slimani N, Deharveng G, Unwin I, et al. The EPIC nutrient database project (ENDB): a first
433 attempt to standardize nutrient databases across the 10 European countries participating in the
434 EPIC study. *European journal of clinical nutrition*. 2007;61(9):1037-1056.
- 435 24. InterAct C, Romaguera D, Guevara M, et al. Mediterranean diet and type 2 diabetes risk in
436 the European Prospective Investigation into Cancer and Nutrition (EPIC) study: the InterAct
437 project. *Diabetes care*. 2011;34(9):1913-1918.
- 438 25. Esposito K, Maiorino MI, Ciotola M, et al. Effects of a Mediterranean-style diet on the need
439 for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: a
440 randomized trial. *Annals of internal medicine*. 2009;151(5):306-314.
- 441 26. Buckland G, Agudo A, Lujan L, et al. Adherence to a Mediterranean diet and risk of gastric
442 adenocarcinoma within the European Prospective Investigation into Cancer and Nutrition
443 (EPIC) cohort study. *The American journal of clinical nutrition*. 2010;91(2):381-390.
- 444 27. Trichopoulou A, Costacou T, Bamia C, Trichopoulos D. Adherence to a Mediterranean diet
445 and survival in a Greek population. *The New England journal of medicine*.
446 2003;348(26):2599-2608.
- 447 28. Wareham NJ, Jakes RW, Rennie KL, et al. Validity and repeatability of a simple index derived
448 from the short physical activity questionnaire used in the European Prospective Investigation
449 into Cancer and Nutrition (EPIC) study. *Public health nutrition*. 2003;6(4):407-413.
- 450 29. Pischon T, Boeing H, Hoffmann K, et al. General and abdominal adiposity and risk of death
451 in Europe. *The New England journal of medicine*. 2008;359(20):2105-2120.
- 452 30. Harrell FEJ. *Regression Modeling Strategies: With Applications to Linear Models, Logistic*
453 *Regression, and Survival Analysis*. New York: Springer; 2001.
- 454 31. Lambert PC, Royston P. Further Development of Flexible Parametric Models for Survival
455 Analysis. *The Stata Journal*. 2009;9(2):265-290.
- 456 32. Grøntved A, Rasmussen MG, Blond K, Østergaard L, Andersen ZJ, Møller NC. Bicycling for
457 Transportation and Recreation in Cardiovascular Disease Prevention. *Current Cardiovascular*
458 *Risk Reports*. 2019;13(26).

- 459 33. Andersen ZJ, de Nazelle A, Mendez MA, et al. A study of the combined effects of physical
460 activity and air pollution on mortality in elderly urban residents: the Danish Diet, Cancer, and
461 Health Cohort. *Environ Health Perspect.* 2015;123(6):557-563.
- 462 34. Koolhaas CM, Dhana K, Schoufour JD, et al. Physical activity and cause-specific mortality:
463 the Rotterdam Study. *Int J Epidemiol.* 2018;47(5):1705-1713.
- 464 35. Oja P, Kelly P, Pedisic Z, et al. Associations of specific types of sports and exercise with all-
465 cause and cardiovascular-disease mortality: a cohort study of 80 306 British adults. *British*
466 *journal of sports medicine.* 2017;51(10):812-817.
- 467 36. Sahlqvist S, Goodman A, Simmons RK, et al. The association of cycling with all-cause,
468 cardiovascular and cancer mortality: findings from the population-based EPIC-Norfolk
469 cohort. *BMJ open.* 2013;3(11):e003797.
- 470 37. Ostergaard L, Jensen MK, Overvad K, Tjonneland A, Grontved A. Associations Between
471 Changes in Cycling and All-Cause Mortality Risk. *American journal of preventive medicine.*
472 2018;55(5):615-623.
- 473 38. Schnohr P, Marott JL, Jensen JS, Jensen GB. Intensity versus duration of cycling, impact on
474 all-cause and coronary heart disease mortality: the Copenhagen City Heart Study. *European*
475 *journal of preventive cardiology.* 2012;19(1):73-80.
- 476 39. Hu G, Jousilahti P, Barengo NC, Qiao Q, Lakka TA, Tuomilehto J. Physical activity,
477 cardiovascular risk factors, and mortality among Finnish adults with diabetes. *Diabetes care.*
478 2005;28(4):799-805.
- 479 40. Jonker JT, De Laet C, Franco OH, Peeters A, Mackenbach J, Nusselder WJ. Physical activity
480 and life expectancy with and without diabetes: life table analysis of the Framingham Heart
481 Study. *Diabetes care.* 2006;29(1):38-43.
- 482 41. Nelson KM, Boyko EJ, Koepsell T. All-cause mortality risk among a national sample of
483 individuals with diabetes. *Diabetes care.* 2010;33(11):2360-2364.
- 484 42. Smith TC, Wingard DL, Smith B, Kritz-Silverstein D, Barrett-Connor E. Walking decreased
485 risk of cardiovascular disease mortality in older adults with diabetes. *J Clin Epidemiol.*
486 2007;60(3):309-317.
- 487 43. Tanasescu M, Leitzmann MF, Rimm EB, Hu FB. Physical activity in relation to
488 cardiovascular disease and total mortality among men with type 2 diabetes. *Circulation.*
489 2003;107(19):2435-2439.
- 490 44. Trichopoulou A, Psaltopoulou T, Orfanos P, Trichopoulos D. Diet and physical activity in
491 relation to overall mortality amongst adult diabetics in a general population cohort. *Journal*
492 *of internal medicine.* 2006;259(6):583-591.
- 493 45. Wei M, Schwertner HA, Blair SN. The association between physical activity, physical fitness,
494 and type 2 diabetes mellitus. *Compr Ther.* 2000;26(3):176-182.
- 495 46. Hu G, Eriksson J, Barengo NC, et al. Occupational, commuting, and leisure-time physical
496 activity in relation to total and cardiovascular mortality among Finnish subjects with type 2
497 diabetes. *Circulation.* 2004;110(6):666-673.
- 498 47. Boule NG, Kenny GP, Haddad E, Wells GA, Sigal RJ. Meta-analysis of the effect of
499 structured exercise training on cardiorespiratory fitness in Type 2 diabetes mellitus.
500 *Diabetologia.* 2003;46(8):1071-1081.
- 501 48. Church TS, Cheng YJ, Earnest CP, et al. Exercise capacity and body composition as predictors
502 of mortality among men with diabetes. *Diabetes care.* 2004;27(1):83-88.
- 503 49. Gaither TW, Sanford TA, Awad MA, et al. Estimated total costs from non-fatal and fatal
504 bicycle crashes in the USA: 1997-2013. *Inj Prev.* 2018;24(2):135-141.
- 505 50. Pope CA, 3rd, Ezzati M, Dockery DW. Fine-particulate air pollution and life expectancy in
506 the United States. *The New England journal of medicine.* 2009;360(4):376-386.

- 507 51. Di Q, Wang Y, Zanobetti A, et al. Air Pollution and Mortality in the Medicare Population. *The New England journal of medicine*. 2017;376(26):2513-2522.
- 508
- 509 52. Sinharay R, Gong J, Barratt B, et al. Respiratory and cardiovascular responses to walking
510 down a traffic-polluted road compared with walking in a traffic-free area in participants aged
511 60 years and older with chronic lung or heart disease and age-matched healthy controls: a
512 randomised, crossover study. *Lancet*. 2018;391(10118):339-349.
- 513 53. Kubesch NJ, de Nazelle A, Westerdahl D, et al. Respiratory and inflammatory responses to
514 short-term exposure to traffic-related air pollution with and without moderate physical
515 activity. *Occup Environ Med*. 2015;72(4):284-293.
- 516 54. Laeremans M, Dons E, Avila-Palencia I, et al. Short-term effects of physical activity, air
517 pollution and their interaction on the cardiovascular and respiratory system. *Environ Int*.
518 2018;117:82-90.
- 519 55. Kubesch N, De Nazelle A, Guerra S, et al. Arterial blood pressure responses to short-term
520 exposure to low and high traffic-related air pollution with and without moderate physical
521 activity. *European journal of preventive cardiology*. 2015;22(5):548-557.
- 522 56. Kubesch NJ, Therning Jorgensen J, Hoffmann B, et al. Effects of Leisure-Time and
523 Transport-Related Physical Activities on the Risk of Incident and Recurrent Myocardial
524 Infarction and Interaction With Traffic-Related Air Pollution: A Cohort Study. *Journal of the
525 American Heart Association*. 2018;7(15).
- 526 57. Sun S, Cao W, Qiu H, et al. Benefits of physical activity not affected by air pollution: a
527 prospective cohort study. *Int J Epidemiol*. 2020;49(1):142-152.
- 528 58. Laeremans M, Dons E, Avila-Palencia I, et al. Black Carbon Reduces the Beneficial Effect of
529 Physical Activity on Lung Function. *Medicine and science in sports and exercise*.
530 2018;50(9):1875-1881.
- 531 59. Fisher JE, Loft S, Ulrik CS, et al. Physical Activity, Air Pollution, and the Risk of Asthma
532 and Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med*. 2016;194(7):855-
533 865.
- 534 60. Welsh C, Celis-Morales CA, Ho F, et al. Association of injury related hospital admissions
535 with commuting by bicycle in the UK: prospective population based study. *BMJ (Clinical
536 research ed.)*. 2020;368:m336.
- 537 61. Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for
538 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation
539 Diabetes Atlas, 9(th) edition. *Diabetes research and clinical practice*. 2019;157:107843.
- 540 62. Espeland MA, Glick HA, Bertoni A, et al. Impact of an intensive lifestyle intervention on use
541 and cost of medical services among overweight and obese adults with type 2 diabetes: the
542 action for health in diabetes. *Diabetes care*. 2014;37(9):2548-2556.
- 543 63. Zimmet P, Alberti KG, Magliano DJ, Bennett PH. Diabetes mellitus statistics on prevalence
544 and mortality: facts and fallacies. *Nat Rev Endocrinol*. 2016;12(10):616-622.
- 545

546 Figure legends

547

548 **Figure 1** Post hoc analyses of the relationships between cycling (hours/week) or leisure time physical
549 activity (LTPA) excluding cycling (metabolic equivalent of tasks per week (MET hours/week)) and
550 all-cause mortality (Panel A and B) or cardiovascular (CVD) mortality (Panel C and D) based on
551 Model 2. Solid lines are hazard ratios (HR) and dotted lines are the upper and lower bounds of the

552 95% confidence intervals (CI). Restricted cubic splines were applied (knot placements in the analyses
553 were 0.5, 2.0, 7.5 hours/week and 21.1, 74.3 and 150.8 met*hours per week for cycling and LTPA,
554 respectively).

555

556

557 **Figure 2** The association between all-cause or cardiovascular mortality and changes in cycling from
558 the baseline to the 2nd examination. Data are presented as hazard ratios with 95% confidence intervals
559 (error bars). Person-years of follow-up/ N_{cases} all-cause mortality/ N_{cases} cardiovascular mortality for
560 non-cyclists (35,674/598/247), those who stopped (5,923/138/78), started (3,571/49/19), or
561 maintained cycling (12,635/190/85). Median minutes (interquartile range) of weekly cycling at
562 baseline were 0 (0-0), 90 (60-180), 0 (0-0) and 150 (90-300) minutes for non-cyclists, those who
563 stopped, started or maintained cycling, respectively. Median minutes (interquartile range) of weekly
564 cycling at the 2nd survey 0 (0-0), 0 (0-0), 90 (60-210) and 150 (90-300) minutes for non-cyclists, those
565 who stopped, started or maintained cycling respectively. All-cause mortality rates per 1000 person-
566 years (95% confidence intervals) were 16.8 (15.5, 18.2), 23.3 (19.7, 27.5), 13.7 (10.4, 18.2) and 15.0
567 (13.0, 17.3) for non-cyclists, those who stopped, started or maintained cycling, respectively. The
568 corresponding incidence rates per 1000 person-years (95% confidence intervals) for cardiovascular
569 mortality were 7.0 (6.1, 7.8), 13.2 (10.6, 16.4), 5.3 (3.4, 8.3) and 6.7 (5.4, 8.3), respectively.

570 Model 1 was stratified by study center and adjusted for sex and age (second examination). Model 2
571 was stratified according to study center, baseline adherence to the Mediterranean diet, baseline
572 occupational physical activity, total energy intake and adjusted for sex, age (second examination),
573 baseline educational level, smoking status at both surveys, diabetes duration at the second survey,
574 leisure-time activity (excluding cycling) at both examinations and occupational physical activity at
575 the second examination.

576

577 **Authors contributions:** MR-L, MGR, KB, LBA, SB and LBA contributed to the design and
578 interpretation of the data. MGR performed the statistical data analyses under supervision of AG and
579 MR-L. MG-R, AG and MR-L had access to the final dataset for the study provided by the
580 International Agency for Research on Cancer / World Health Organization and takes responsibility
581 for the integrity of the dataset and the accuracy of the data analysis. MR-L wrote the first draft of the

582 manuscript with contributions from MGR and AG. All authors contributed to a critical revision of the
583 initial manuscript and approved the final version of the report.

584

585 **Reproducible Research Statement** Individual participant data that underlie the results reported in
586 this article, after de-identification (text, tables, figures and appendices) can accessed by contacting
587 the International Agency for Research on Cancer / World Health Organization. Analytic codes are
588 available upon request by contacting the corresponding author. MR-L and MGR had full access to all
589 the data in the study and takes responsibility for the integrity of the data and the accuracy of the data
590 analysis.

591

592 **Conflict of Interest Disclosures** None of the authors reports a conflict of interest

593

594 **Disclaimer** Where authors are identified as personnel of the International Agency for Research on
595 Cancer / World Health Organization, the authors alone are responsible for the views expressed in this
596 article and they do not necessarily represent the decisions, policy or views of the International Agency
597 for Research on Cancer / World Health Organization.

598

599 **Funding/Support** The Center for Physical Activity Research (CFAS) is supported by a grant from
600 TrygFonden. RZ-R was supported by the “Miguel Servet” program (CP15/00100) from the Institute
601 of Health Carlos III (Co-funded by the European Social Fund (ESF) - ESF investing in your future).
602 Spanish funding: Health Research Fund (FIS) - Instituto de Salud Carlos III (ISCIII), Regional
603 Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute
604 of Oncology - ICO (Spain). MBS was supported by a grant from the German Ministry of Education
605 and Research (BMBF) and the State of Brandenburg (DZD grant 82DZD00302)

606

607 **Role of the funding source** The funders had no role in design and conduct of this study; collection,
 608 analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and
 609 decision to submit the manuscript for publication.

610

611 **Additional contributions** We acknowledge and thank the participants as well as study-site personnel
 612 at all EPIC sites for their effort.

613

614

615

616

617

Table 1. Baseline characteristics of sample subgroups and the total cohort

	Weekly time spent cycling at first examination					Total
	0 min.	0-59 min.	60-149 min.	150-299 min.	300+ min.	
N	4,648	422	999	736	654	7,459
Average annual cycling (min./week) [‡]	0 (0-0)	30 (30-30)	90 (60-120)	180 (165-240)	420 (330-600)	0 (0-90)
Sex (% male/female)	42.4/57.6	59.5/40.5	56.2/43.8	54.5/45.5	53.5/46.5	47.4/52.6
Age (years) [†]	55.6 (7.8)	55.0 (7.4)	56.0 (7.9)	56.4 (7.1)	57.3 (6.9)	55.9 (7.7)
Diabetes duration (years) [†]	7.7 (8.1)	7.3 (7.4)	7.7 (8.4)	7.7 (8.1)	7.5 (8.0)	7.7 (8.1)
Education (%)						
None	23.4	1.4	4.2	3.7	2.8	15.8
Primary school completed	35.3	42.4	35.4	40.1	43.9	37.0
Technical/professional school	17.1	23.2	27.7	28.5	29.5	21.1
Secondary school	8.4	10.2	10.7	9.0	8.9	8.9
Longer education (incl. University deg.)	15.9	22.7	21.9	18.8	15.0	17.3
Smoking (%)						
Never	50.8	38.2	40.0	41.3	38.4	46.6
Former	26.7	38.9	37.3	37.0	41.0	31.1
Current	22.4	23.0	22.6	21.7	20.6	22.3
BMI (kg/m ²) [‡]	29.4 (5.1)	28.0 (4.5)	28.2 (4.8)	28.6 (4.6)	28.6 (4.7)	29.0 (5.0)
Waist circumference (cm) [‡]						
Male	101.4 (11.3)	98.8 (10.7)	98.9 (10.8)	99.1 (10.1)	99.3 (11.2)	100.4 (11.1)
Female	92.2 (13.0)	86.7 (12.5)	89.5 (13.5)	92.0 (13.6)	91.6 (12.9)	91.6 (13.1)
Central obesity (N (%) - yes/no)	3681 (79.2)/967 (20.8)	280 (66.4)/142 (33.6)	707 (70.8)/292 (29.2)	558 (75.8)/178 (24.2)	487 (74.5)/167 (25.5)	5,713 (76.6)/1,746 (23.4)
Leisure time physical activity without cycling, MET-h/week [‡]						
Gardening	0.0 (0.0-8.0)	4.0 (0.0-10.0)	4.0 (0.0-14.0)	4.0 (0.0-14.0)	4.0 (0.0-16.0)	0.0 (0.0-11.0)
Do-it-yourself activities	0.0 (0.0-4.5)	4.5 (0.0-13.5)	4.5 (0.0-9.0)	2.3 (0.0-9.0)	0.0 (0.0-13.5)	0.0 (0.0-6.8)
Stair climbing	0.9 (0.0-2.1)	1.0 (0.4-2.6)	1.3 (0.4-2.6)	1.3 (0.3-2.6)	1.3 (0.4-2.6)	1.0 (0.3-2.3)
Housework	30.0 (3.0-84.0)	12.0 (0.0-42.0)	12.0 (6.0-42.0)	15.0 (6.0-45.0)	21.0 (6.0-45.0)	21.0 (3.0-63.0)
Walking	15.0 (6.0-27.0)	10.5 (4.5-21.0)	12.0 (6.0-21.0)	15.0 (9.0-27.0)	21.0 (12.0-36.0)	15.0 (6.0-27.0)
Sports	0.0 (0.0-0.0)	0.0 (0.0-6.0)	0.0 (0.0-9.0)	0.0 (0.0-11.3)	0.0 (0.0-12.0)	0.0 (0.0-6.0)
Occupational physical activity (%)						
Sedentary occupation	21.4	28.7	25.8	23.4	18.2	22.3
Standing occupation	20.7	19.0	17.9	18.6	16.8	19.7
Manual work	9.3	11.6	11.2	11.4	10.6	10.0
Non worker	47.4	40.0	44.2	45.0	51.4	46.7

Unknown	1.2	0.7	0.8	1.6	3.1	1.3
Energy intake (kcal/day) [†]	2025.1 (640.5)	2154.6 (641.9)	2103.0 (631.9)	2072.6 (640.9)	2120.9 (664.6)	2056.0 (642.9)
Adherence to the relative Mediterranean diet score (%)						
Low	16.6	21.1	30.1	28.8	31.0	21.1
Medium	43.2	54.7	49.9	51.4	47.7	45.9
High	40.2	24.2	19.9	19.8	21.3	32.9
Prevalent co-morbidities						
Prevalent cancer (%)	4.4	4.0	3.8	4.6	5.4	4.4
Stroke (%)	3.4	2.6	3.6	2.3	2.4	3.2
Myocardial infarction (%)	4.8	5.5	5.6	5.2	5.4	5.1
Hyperlipidaemia (%)	41.8	46.0	36.1	37.8	38.5	40.6
Hypertension (%)	47.3	48.1	48.5	48.8	53.2	48.2
[†] Mean (standard deviation), [‡] Median (Interquartile range: First quartile-Third quartile), MET-h/week; Metabolic equivalent of task – hours per week, n, number, min, minutes, BMI, body mass index, To convert cm to inches divide by .39						

618

619


Table 2. Association between total volume of cycling at the baseline examination and all-cause and cardiovascular disease mortality

	Weekly time spent cycling at first examination				
	0 min.	1-59 min.	60-149 min.	150-299 min.	300+ min.
N	4,648	422	999	736	654
Person-years	70,741	5,994	14,395	10,521	9,292
Cases – All cause mortality					
	1,059	79	231	150	154
Mortality rate/1000 person-years	14.9 (14.1, 15.9)	13.2 (10.6, 16.4)	16.0 (14.1, 18.3)	14.3 (12.2, 16.7)	16.6 (14.2, 19.4)
Model 1 (HR and (95% CI)) ¹	1 (reference)	0.76 (0.60,0.96)	0.72 (0.62,0.84)	0.65 (0.55,0.78)	0.71 (0.60,0.85)
Model 2 (HR and (95% CI)) ²	1 (reference)	0.78 (0.61,0.99)	0.76 (0.65,0.88)	0.68 (0.57,0.82)	0.76 (0.63,0.91)
Model 3 (HR and (95% CI)) ³	1 (reference)	0.81 (0.64,1.03)	0.77 (0.66,0.90)	0.70 (0.59,0.84)	0.81 (0.68,0.97)
Cases - Cardiovascular mortality					
	499	41	119	66	86
Mortality rate/1000 person-years	7.1 (6.5, 9.3)	6.8 (5.0, 9.3)	8.3 (6.9, 9.9)	6.3 (4.9, 8.0)	9.3 (7.5, 11.4)
Model 1 (HR and (95% CI)) ¹	1 (reference)	0.72 (0.52,1.00)	0.72 (0.59,0.89)	0.55 (0.42,0.71)	0.75 (0.59,0.96)
Model 2 (HR and (95% CI)) ⁴	1 (reference)	0.79 (0.56,1.11)	0.75 (0.60,0.93)	0.57 (0.44,0.76)	0.80 (0.62,1.03)
Model 3 (HR and (95% CI)) ⁵	1 (reference)	0.83 (0.59,1.18)	0.78 (0.63,0.98)	0.61 (0.46,0.81)	0.91 (0.70,1.17)
<p>HR; Hazard ratio, CI; Confidence interval, N, number for persons; min., minutes *Median and interquartile range</p> <p>¹ Stratified according to study center and adjusted for sex and age</p> <p>² Stratified according to study center and total energy intake (quartiles of kcal/week). Adjusted for sex, age, educational level, smoking status, diabetes duration, adherence to the Mediterranean diet, leisure-time (excluding cycling) and occupational physical activity</p> <p>³ Stratified according to study center and total energy intake (quartiles of kcal/week). Adjusted for sex, age, educational level, smoking status, diabetes duration, adherence to the Mediterranean diet, leisure-time (excluding cycling) and occupational physical activity, prevalent stroke, prevalent myocardia infarction, prevalent cancer, hyperlipidemia, hypertension and central obesity</p> <p>⁴ Stratified according to study center, educational level, and leisure-time physical activity (excluding cycling). Adjusted for sex, age, smoking status, diabetes duration, adherence to the Mediterranean diet, total energy intake and occupational physical activity</p> <p>⁵ Stratified according to study center, educational level, and leisure-time physical activity (excluding cycling). Adjusted for sex, age, smoking status, diabetes duration, adherence to the Mediterranean diet, total energy intake and occupational physical activity, prevalent stroke, prevalent myocardia infarction, prevalent cancer, hyperlipidemia, hypertension and central obesity</p> <p>Exposure variables were obtained at the baseline (1st) examination</p>					

620


621

622 Fig 1:



623
624

625 Fig 2:



626